Articles tagged with Hiv Research
Researchers at the University of North Carolina and partner institutions have made significant strides in understanding HIV latency, a key obstacle to eradicating the virus. The team has developed effective strategies, including histone deacetylase inhibitors, to reverse latency and boost the immune system.
Drs. Henry Boom and Moses Joloba at Case Western Reserve University and Makerere University, respectively, have received a $1.5 million five-year grant to strengthen Ugandan biomedical research capacity. The program aims to provide PhD-level training in microbiology and immunology to talented young Ugandan scientists.
The study confirms on-demand PrEP is a highly effective method of reducing the risk of HIV infection. The results show an incidence rate of 0.19 infections per 100 person-years of follow-up, with a significant drop in condom use among participants.
The ANRS 162-4D trial found that patients on a 4-day a week regimen had undetectable viral loads for most of the study period. The innovative strategy aims to improve adherence and reduce drug burden, but more research is needed to confirm its efficacy.
Using a drug-infused vaginal ring most of the time significantly reduced HIV infection risk in women by at least 56 percent, according to an exploratory analysis of data from the ASPIRE study. High adherence was associated with a risk reduction of potentially 75 percent or more.
The HOPE study will build on the ASPIRE trial results, gathering more information on the dapivirine ring's safety and effectiveness in reducing HIV risk. The study aims to understand why the ring works for some women but not others.
Researchers found that using the dapivirine ring consistently provided significant protection against HIV, with high adherence associated with better HIV protection. The study's results coincide with the start of the HOPE open-label study, which will gather additional information on the ring's safety and effectiveness.
Researchers from UCLA have discovered a type of cell called chimeric antigen receptors that can be used to kill HIV-infected cells. CARs are artificially created immune T cells engineered to produce receptors designed to target and kill specific cells containing viruses or tumor proteins.
A daily PrEP pill can reduce new HIV cases among men who have sex with men (MSM) by a third in the US over 10 years if guidelines are followed, according to a modeling study. The medication is highly effective in preventing HIV infection when used consistently.
Research suggests that prisoners are released without access to medications that control their illnesses, leading to a spike in viral loads and increased risk of transmission. Decreasing incarceration rates for people who inject drugs could reduce the burden of HIV among prisoners.
A new discovery has identified cell markers to target HIV reservoirs, opening new treatment perspectives. The study found that using antibodies specifically binding to these markers could destroy HIV reservoirs and potentially cure infected individuals by allowing them to stop antiretroviral therapy.
The National Institutes of Health has awarded $30 million in annual funding to six international collaborations working on an HIV cure. The program aims to address the virus's ability to establish a reservoir in immune cells, making it challenging to develop a cure.
Researchers from George Washington University have received a $28 million grant to develop an innovative cell therapy approach to eliminate HIV reservoirs. The project, named 'BELIEVE,' aims to enhance the immune system's ability to kill HIV-infected cells.
Researchers at UNC Chapel Hill will receive nearly $23 million over five years to study the 'kick and kill' strategy for eradicating HIV. The approach involves waking up latent viruses and boosting the immune system to recognize and clear them.
The US Army's MHRP is part of a collaborative research team awarded $4.6M per year to develop an integrated approach to finding an HIV cure. Researchers will study immune responses generated by therapeutic vaccines and broadly neutralizing antibodies.
Scientists discover galectin-9 potently forces latent HIV out of hiding and poisons the virus, increasing APOBEC3G levels to destroy genetic code. This 'shock and kill' strategy holds promise for a cure, altering treatment approach to eliminate all viral traces from the body.
Researchers are working on vaccines that induce broadly neutralizing antibodies to block a wide range of HIV variants, but the body does not readily make an adequate immune response to HIV infection. Efforts to vaccinate individuals with HIV immunogens have not yet been successful due to this issue.
A new study by Columbia University's Mailman School of Public Health found that financial incentives did not improve health outcomes for HIV-positive people with substance use disorders. The study showed no statistical differences in rates of viral suppression versus non-suppression or death among trial arms.
A new study confirms the efficacy of the RV144 HIV vaccine in macaques, disproving the notion that a stronger adjuvant yields better results. The study found that changing the adjuvant did not improve the vaccine's effectiveness, but instead triggered an immune response at the site of infection.
Jonathan Karn, PhD, an HIV/AIDS expert, has received two Innovation research grants to better understand and ultimately curtail HIV's ability to remain in the body as a persistent viral reservoir. The goal is to shrink the size of, and eventually eliminate the reservoir using hormone therapies.
The Quatro Study will inform ongoing product development efforts by gathering end-user input on four vaginal delivery systems for HIV and multipurpose prevention. The study, recruiting 200 healthy women ages 18-30 in South Africa and Zimbabwe, assesses user experiences of placebos with no active ingredients.
A NIH-led team studied implementation science approaches to prevent mother-to-child HIV transmission, identifying effective interventions such as baby showers and breastfeeding support. The study found that deploying point-of-care tests and administering pre-exposure prophylaxis were likely cost-effective and resulted in timely initiat...
Researchers at TSRI have advanced efforts to design an AIDS vaccine by stabilizing the HIV Envelope glycoprotein trimer and designing novel nanoparticles that mimic the virus. The stabilization strategy improves the protein's properties, allowing for the creation of HIV-like particles that can prompt the body to fight the real virus.
A new study by NYU researchers found that only 8.3% of high school seniors reported past-year nonmedical opioid use, but when accounting for discordant responses, the prevalence rate is estimated to be 11.1%. This underestimation highlights the need for better drug education and more accurate data to combat the opioid crisis.
A new intervention aims to increase engagement with treatment among African-American/black and Hispanic people living with HIV. The study will use a pioneering engineering-inspired framework - the Multiphase Optimization Strategy (MOST) -- to identify effective components and build the most cost-effective package.
Researchers at NYU and Penn State aim to increase engagement in HIV care for African American/Black and Hispanic Patients Living with HIV using a pioneering framework. The study will identify effective intervention components, mediators, and moderators to build the most cost-effective package.
A Johns Hopkins study of 28,000 people with HIV concludes that the Ryan White HIV/AIDS Program remains crucial despite the Affordable Care Act's availability. The program provides free medical care to hundreds of thousands of low-income individuals, and its cutbacks could leave many without access to essential services.
A prospective, multinational study investigating virological and immunological changes due to HIV prior to clinical symptoms has identified 112 people with newly acquired infections just days after HIV exposure. The study provides valuable insights into the early stages of HIV infection and its impact on immune defense mechanisms.
A Phase II trial found that autologous stem cell transplant is effective and safe for HIV patients with relapsed/treatment-resistant lymphoma. Patients with HIV had comparable overall survival rates and reduced toxicity compared to non-HIV patients.
Researchers found that half of people newly infected with HIV experience mild to moderate neurologic issues, which usually resolve after starting anti-retroviral therapy. These findings suggest that HIV affects the nervous system within days of infection.
Seven pioneers in HIV/AIDS and epigenetics research receive NIDA's Avenir awards to support groundbreaking projects using genome editing, smartphones, and smart health technologies. These early-stage investigators will receive up to $300,000 per year for five years to advance addiction science.
Researchers at Mount Sinai have shown how infected immune cells directly transmit newly minted viral particles to uninfected sister cells, spreading the virus efficiently. This study highlights cell-to-cell transmission as a key route for HIV spread and may help develop new treatments.
Researchers used RNA simulations to understand how viruses fold into specific shapes, offering potential targets for treating retroviral diseases. The study's findings provide valuable information on the thermodynamic stability of RNA molecules and their behavior in different environments.
The University at Buffalo has partnered with the University of Zimbabwe to launch a five-year HIV research training program, supported by a $1.3 million NIH grant. The program aims to train future HIV researchers and address issues such as maternal-fetal transmission, resistance, and co-infection in Zimbabwe.
A large clinical trial is set to begin in November 2016 to determine the safety and effectiveness of an investigational HIV vaccine regimen. The study, called HVTN 702, will enroll 5,400 adults at risk for HIV infection and assess the regimen's ability to prevent HIV infection among South African adults.
Researchers at Rutgers University and Dartmouth College find that oral drug deferiprone kills HIV-infected cells in lab cultures and suppresses the virus in patients in a limited clinical trial. The treatment approach has potential as a new strategy for destroying the DNA harbored in HIV-infected cells.
Scientists from KU Leuven discover a new way to treat HIV by blocking the virus's attachment to genetic material. Led by Professor Zeger Debyser and Doctoral student Lenard Vranckx, their research sheds light on eliminating the virus.
A recent study highlights the persistence of syphilis in sub-Saharan Africa, where rates have remained higher than in other regions. The research suggests that common risk factors, such as HIV prevalence and connected sexual networks, may be underlying causes of the spread of syphilis in these populations.
Research associates BPD with higher rates of STI/HIV transmission and multiple partnerships, particularly fear of abandonment and impulsivity symptoms. The study highlights the need for proper assessment and diagnosis of BPD to develop targeted interventions for this population.
A Phase 1 clinical trial shows that an antibody-based drug can stimulate patients' immune response, enabling them to make new or better antibodies against HIV. The researchers also found that the antibody was able to engage immune cells and accelerate their clearance of HIV-infected cells.
The US saw an 11% decrease in new HIV infections and a 17% drop in transmission rates from 2010 to 2015. However, the country fell short of its goal to reduce these numbers by 25% and 30%, respectively.
A University of Pennsylvania study examined intimate partner violence and relationship power among South African adolescents, finding that girls with lower power were more likely to have multiple partners. The research suggests that targeting gender-specific components in HIV prevention interventions could help reduce transmission rates.
New research reveals that black female college students are reluctant to use online HIV prevention resources, citing stigma and fear of social repercussions. The study's findings highlight the need for culturally sensitive information delivery methods tailored to this demographic.
A study in monkeys exposed to SIV reveals what happens in the very earliest stages of infection, providing insights into vaccine development and prevention. The findings suggest a narrow window of opportunity to contain or eliminate the virus.
Researchers exposed monkeys to SIV, the monkey equivalent of HIV, and found that the virus triggers early host responses that suppress antiviral immunity. This early inflammation promotes viral replication, highlighting the need for effective prevention tools.
Researchers identified six areas for improvement: HIV prevention, common entry points, information availability, funding sources, competiveness, and building trust. Collaboration among agencies was found to be crucial for effective service delivery.
The National Institute of Allergy and Infectious Diseases is conducting two multinational clinical trials to test an investigational anti-HIV antibody called VRC01. The studies aim to determine the safety, tolerability, and effectiveness of the antibody in preventing HIV infection.
The AMP study aims to assess the safety and efficacy of VRC01 in reducing HIV-1 acquisition among at-risk populations. The randomized, double-blind trial will enroll 2700 participants and follow them for up to 72 weeks.
Researchers at TSRI have identified the first-ever immature HIV-neutralizing antibody, revealing a possible guide for developing an effective vaccine. The antibody, found in a Chinese patient, evolved rapidly and gained key traits within two years, contradicting previous theories.
A recent study identifies multiple sexual behaviors associated with prevalent sexually transmitted infections, including HIV. Men who engaged in anal stimulation or enema use were nearly five times as likely to test positive for HIV as those who did not.
Researchers at Temple University Health System have successfully eliminated HIV-1 from the DNA of human T-cells using a specialized gene editing system. The technology not only removes the virus but also protects infected cells against reinfection, holding promise for an eventual cure for patients with HIV.
Researchers developed a new long-acting formulation of raltegravir for pre-exposure prophylaxis, showing significant protection against multiple strains of HIV in animal models. The study found that the injectable provided strong suppression of viral load and could potentially improve adherence to medication regimens.
A large clinical trial found that treating HIV patients at risk for tuberculosis with TB drugs does not save more lives. Simple TB screening and isoniazid preventive therapy were well-tolerated and resulted in similar survival rates compared to a four-drug TB treatment.
Researchers found that a family-focused package of services can significantly reduce mother-to-child transmission of HIV in resource-limited areas. The study showed a 74% reduction in infant infections in the intervention group compared to the control group.
Researchers at UNC School of Medicine have demonstrated that HIV infects and replicates in macrophages, a discovery with significant implications for HIV cure research. The study found that macrophages can sustain HIV replication in the absence of T cells and can establish infection in new hosts.
The study reveals the high-resolution structure of the HIV envelope protein, known as the Env trimer, in its natural form for the first time. The findings also include a detailed map of a vulnerable site at the base of this protein and the binding site of an antibody that can neutralize HIV.
A research team has identified rare potent antibodies in an HIV-infected individual and determined sequential structures that point to how they developed. This finding will help guide researchers as they try to build an experimental vaccine that recreates the pathway that gives rise to these important broadly neutralizing antibodies.
A reduced glycerin formulation of tenofovir gel was found safe when used daily and around the time of sex for HIV prevention. Participants were as likely to follow through using the gel with sex as they were taking daily oral PrEP, demonstrating its potential as a rectal microbicide for people at risk of HIV from anal sex.
A Phase 2 trial found that maraviroc-containing regimens are as safe and well-tolerated as TDF and emtricitabine when used as PrEP to prevent HIV infection in high-risk men. Five participants became infected with HIV during the study, but their low drug levels suggested inconsistent use of PrEP.
A novel coordinated care program helped black men who have sex with men adhere to pre-exposure prophylaxis (PrEP), a medication regimen that prevents HIV infection. Nearly 80% of participants agreed to take PrEP, and 70% had protective levels in their plasma at the midpoint.